Revenue up 24.6% Y-o-Y to INR 5,827.4 Mn, Operating EBITDA at INR 1,095.5 Mn
Chennai, August 10, 2019: TAKE Solutions Ltd. [BSE: 532890 | NSE: TAKE], a globally recognized domain intensive services provider in Life Sciences, today announced its Q1 FY20 financial results. The company posted quarterly revenue of INR 5,827.4 Mn, registering a growth of 9.1% compared to the previous quarter.
Consolidated Financial Highlights – Figures in INR Million
| Particulars | Figures in | Q1 FY20 | Q4 FY19 | Change (%) |
| Q-o-Q | ||||
| Op. Revenue | INR Mn | 5,827.4 | 5,339.4 | 9.1% |
| USD Mn | 83.6 | 76.4 | 9.5% | |
| Op. EBITDA | INR Mn | 1,095.5 | 996.2* | 10.0% |
| Margin | % | 18.8% | 18.7% | |
| Net Profit (PAT) | INR Mn | 460.8 | 270.6 | 70.3% |
| Margin | % | 7.9% | 5.1% | |
| Diluted EPS | INR | 3.08 | 1.89 | 63.0% |
*Adjusted Op. EBITDA
The reported Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) for Q1FY20 stood at INR 1,103.7 Mn, as against INR 830.2 Mn after considering all one-time expenses in the previous quarter.
Srinivasan H R, Vice Chairman and Managing Director, TAKE Solutions said, “TAKE has seen strong numbers in terms of revenue growth this. We are on track in terms of our vision to be a 500 million- dollar enterprise by 2021 and have achieved USD 83.6 Mn this quarter. Company sustained its growth in revenues and profits on account of the business strengthening initiatives of the earlier years that now came to fruition.”
He also added, ”As a Life Sciences company actively engaged in R&D, we have been reclassified under the Pharmaceuticals Industry on both the BSE and NSE.”
Key Highlights:
- 2 of the Top 5 Pharma companies have renewed Long Term Multi-million-dollar contracts till 2022
- TAKE’s key brand Navitas Life Sciences is recognized as a Major Contender within 3 years of launching as a full-service Clinical Research Organization by Everest Group PEAK Matrix Assessment 2019
Corporate Comm India (CCI Newswire)
